DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for enthesopathy — screening already-approved drugs against its 12-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEnthesopathy maps to a 12-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for enthesopathy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
DNA polymerase alpha 1, catalytic subunit (POLA1) — POLA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QJ7 · 3.07 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
A 1980 German paper reports that proliferation therapy with hypertonic glucose has been found very successful in treating enthesopathies that are primarily refractory to therapy. The authors state that animal experiments showed glucose produces only mild irritation and leads to the formation of inert, non-excessive scar tissue. They contrast this with corticosteroids, which they say can cause tissue damage. No patient numbers, response rates, or controlled comparisons are given in that abstract.
A 1998 paper describes two patients with shoulder trauma followed by severe chronic pain who were diagnosed with traumatic enthesopathy and responded well to sclerosing therapy. The abstract gives no further detail on the agent used, the duration of response, or any quantitative outcome. Two case reports provide no basis for generalisation.
Two 2011 review articles describe enthesopathy as a variety of syndromes occurring in the course of many rheumatic, metabolic, and endocrine disorders. They note that calcium deposition diseases may be the most significant articular cause of enthesopathies in the general population, and that enthesis involvement in rheumatoid arthritis is overshadowed by synovitis. The pathogenic mechanisms are not uniform and differ across disorders. No treatment data are presented in these reviews.
What is missing: no randomised trials of any therapy for enthesopathy are cited; no validated patient-reported outcome measures specific to enthesopathy are tested; no stratification by underlying disease (spondyloarthropathy, metabolic, traumatic) has been attempted in a treatment study; funding for a controlled trial of sclerosing or proliferation therapy has not been reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Aktuelle Rheumatologie · 1980 · 4 citations
Proliferationstherapie bei Enthesopathien
AbstractEnthesis or insertion of the muscle is an important functional and anatomic structure in the kybernetic regulation of the locomotor system. Pathological changes in the tendinous insertion, i.e. enthesopathies, possess a well-defined nosology. Although local therapy is important, it will not be enough to concentrate therapeutic efforts exclusively on the site of the pathological condition. Rather, it will be necessary to intervene in the entire pathogenetic circle. A distinction must be made between primary or secondary enthesopathy. Proliferation therapy with hypertonic glucose has been found very successful in the treatment of enthesopathies which are primarily refractory to therapy. Glucose infiltrations into the insertions were employed because animal experiments have shown that glucose produces only mild irritation and leads to the formation of inert, non-exclusive cicatricial tissue. Local therapy must be effected with preparations which do not harm the tissue, so that damage is avoided as, for example, in the case of infiltration with corticoids. Zusammenfassung Enthesis oder Insertio des Muskels ist eine wichtige funktionelle und anatomische Struktur in der kybernetischen Regulation des Bewegungssystems. Pathologische Veränderungen im Sehnenansatz, d. h. Enthesopathien, haben eine gut abgrenzbare Nosologie. Eine lokal ausgerichtete Therapie ist wichtig, jedoch nicht ausreichend. Es ist vielmehr notwendig, in den gesamten pathogenetischen Kreis einzugreifen. Dabei ist zu unterscheiden, ob es sich um eine primäre oder um eine sekundäre Enthesopathie handelt. Bei der primären therapieresistenten Enthesopathie hat sich die Proliferationstherapie mit hypertonischer Glukose als sehr erfolgreich erwiesen, weil im Tierexperiment nachgewiesen worden ist, daß Glukose nur einen leichten Reizzustand verursacht und zur Bildung von inertem, nicht überschüssigem Narbengewebe führt. Die lokale Therapie muß mit gewebefreundlichen Mitteln durchgeführt werden, da es sonst zu Schädigungen wie z. B. bei Infiltration mit Kortikoiden kommen kann.
Journal of Musculoskeletal Pain · 1998 · 0 citations
Two Cases of Uncommon Traumatic Enthesopathy
AbstractAbstractBackground: Traumatic enthesopathy is an injury at the attachment of a tendon or ligament into bone. Untreated, it can lead to chronic pain.Findings: Two patients with trauma to the shoulder followed by severe chronic pain were diagnosed with traumatic enthesopathy and responded well to appropriate therapy.Conclusions: Diagnosis of traumatic enthesopathy is made by analysis of the mechanism of injury and by palpation of the involved area. Treatment of enthesopathy with sclerosing therapy is rapidly effective.KEYWORDS: Uncommon entfaesopatliyenthesopathychronic painsclerosant therapy
Indian Journal of Rheumatology · 2011 · 0 citations · open access
P84 Learning to live with chronic disease: experience from BARC, an evidence-based patient education and support service
AbstractThe concept of “enthesis organ” allows a new look at the nature of enthesis involvement in some rheumatic and nonrheumatic systemic disorders.To describe the various presentations of enthesopathy in the course of systemic medical disorders using the available literature data.Review of relevant articles from 1996 to 2006 retrieved by a Medline search utilizing the index terms “enthesis,” “enthesitis,” and “tendonitis.” The list of articles reviewed herein is not exhaustive, with preference given, where possible, to studies and surveys over case reports as well as the most recent literature reflecting new developments on the subject.Enthesis is defined as the site of insertion of a tendon, ligament, fascia, or articular capsule into bone. Pain originating in the free nerve endings enriched entheses (enthesalgia) may represent a potential cause of chronic musculoskeletal pain in some individuals.Enthesis involvement in the disease process is well appreciated in spondyloarthropathies and in rheumatoid arthritis, though overshadowed by synovitis in the latter. Calcium deposition diseases may constitute the most significant articular cause of enthesopathies in the general population. New data may shed light on the possible pathophysiologic role of enthesopathy in the development of osteoarthritis. Various metabolic and endocrine conditions may manifest with enthesopathy features. The pathogenic mechanisms of enthesis involvement are not uniform and differ in the diverse disorders.The concept of enthesopathy as a variety of syndromes in the course of many rheumatic, metabolic, and endocrine disorders should be appreciated. Exercise of a high level of suspicion toward enthesopathic involvement, and greater knowledge of enthesopathy’s characteristic patterns and diagnostic possibilities, may allow better management of many patients in rheumatology practice.
Indian Journal of Rheumatology · 2011 · 0 citations · open access
P82 Audit of patient-reported outcome measures (proms) in chronic musculoskeletal disease clinics
AbstractThe concept of “enthesis organ” allows a new look at the nature of enthesis involvement in some rheumatic and nonrheumatic systemic disorders.To describe the various presentations of enthesopathy in the course of systemic medical disorders using the available literature data.Review of relevant articles from 1996 to 2006 retrieved by a Medline search utilizing the index terms “enthesis,” “enthesitis,” and “tendonitis.” The list of articles reviewed herein is not exhaustive, with preference given, where possible, to studies and surveys over case reports as well as the most recent literature reflecting new developments on the subject.Enthesis is defined as the site of insertion of a tendon, ligament, fascia, or articular capsule into bone. Pain originating in the free nerve endings enriched entheses (enthesalgia) may represent a potential cause of chronic musculoskeletal pain in some individuals.Enthesis involvement in the disease process is well appreciated in spondyloarthropathies and in rheumatoid arthritis, though overshadowed by synovitis in the latter. Calcium deposition diseases may constitute the most significant articular cause of enthesopathies in the general population. New data may shed light on the possible pathophysiologic role of enthesopathy in the development of osteoarthritis. Various metabolic and endocrine conditions may manifest with enthesopathy features. The pathogenic mechanisms of enthesis involvement are not uniform and differ in the diverse disorders.The concept of enthesopathy as a variety of syndromes in the course of many rheumatic, metabolic, and endocrine disorders should be appreciated. Exercise of a high level of suspicion toward enthesopathic involvement, and greater knowledge of enthesopathy’s characteristic patterns and diagnostic possibilities, may allow better management of many patients in rheumatology practice.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
